CL2012000797A1 - Compuestos derivados de pirazol, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que los comprende; y su uso para el tratamiento de una enfermedad o condicion tal como sindrome metabolico, diabetes, resistencia a la insulina, complicaciones diabeticas y trastornos del peso corporal. - Google Patents
Compuestos derivados de pirazol, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que los comprende; y su uso para el tratamiento de una enfermedad o condicion tal como sindrome metabolico, diabetes, resistencia a la insulina, complicaciones diabeticas y trastornos del peso corporal.Info
- Publication number
- CL2012000797A1 CL2012000797A1 CL2012000797A CL2012000797A CL2012000797A1 CL 2012000797 A1 CL2012000797 A1 CL 2012000797A1 CL 2012000797 A CL2012000797 A CL 2012000797A CL 2012000797 A CL2012000797 A CL 2012000797A CL 2012000797 A1 CL2012000797 A1 CL 2012000797A1
- Authority
- CL
- Chile
- Prior art keywords
- desaturase
- stearoyl
- coa
- pyrazole
- modulators
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 208000002249 Diabetes Complications Diseases 0.000 title 1
- 206010012655 Diabetic complications Diseases 0.000 title 1
- 108010087894 Fatty acid desaturases Proteins 0.000 title 1
- 206010022489 Insulin Resistance Diseases 0.000 title 1
- 208000001145 Metabolic Syndrome Diseases 0.000 title 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 title 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title 1
- 230000037396 body weight Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24763409P | 2009-10-01 | 2009-10-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012000797A1 true CL2012000797A1 (es) | 2013-08-09 |
Family
ID=43066810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012000797A CL2012000797A1 (es) | 2009-10-01 | 2012-03-30 | Compuestos derivados de pirazol, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que los comprende; y su uso para el tratamiento de una enfermedad o condicion tal como sindrome metabolico, diabetes, resistencia a la insulina, complicaciones diabeticas y trastornos del peso corporal. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20130011361A1 (es) |
| EP (1) | EP2483264A1 (es) |
| JP (1) | JP2013506638A (es) |
| KR (1) | KR20120080226A (es) |
| CN (1) | CN102574841A (es) |
| AU (1) | AU2010302577A1 (es) |
| BR (1) | BR112012007509A2 (es) |
| CA (1) | CA2776294A1 (es) |
| CL (1) | CL2012000797A1 (es) |
| CO (1) | CO6761294A2 (es) |
| CR (1) | CR20120134A (es) |
| EA (1) | EA201200545A1 (es) |
| EC (1) | ECSP12011837A (es) |
| IL (1) | IL218294A0 (es) |
| IN (1) | IN2012DN01913A (es) |
| MA (1) | MA33693B1 (es) |
| MX (1) | MX2012003938A (es) |
| PE (1) | PE20121439A1 (es) |
| SG (1) | SG178869A1 (es) |
| TN (1) | TN2012000085A1 (es) |
| WO (1) | WO2011039358A1 (es) |
| ZA (1) | ZA201201390B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6254087B2 (ja) | 2011-10-15 | 2017-12-27 | ジェネンテック， インコーポレイテッド | 癌を治療するためのｓｃｄ１アンタゴニスト |
| JP2019533022A (ja) | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| EP3566055A4 (en) | 2017-01-06 | 2020-12-02 | Yumanity Therapeutics, Inc. | TREATMENT METHODS FOR NEUROLOGICAL DISORDERS |
| EP3700934A4 (en) | 2017-10-24 | 2021-10-27 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THESE COMPOUNDS |
| MX2020009942A (es) * | 2018-03-23 | 2021-01-08 | Yumanity Therapeutics Inc | Compuestos y usos de los mismos. |
| GB202012969D0 (en) * | 2020-08-19 | 2020-09-30 | Univ Of Oxford | Inhibitor compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1171465E (pt) | 1999-03-29 | 2004-12-31 | Uutech Ltd | Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes |
| RU2269354C2 (ru) | 1999-09-28 | 2006-02-10 | Байер Корпорейшн | Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения |
| AU4722801A (en) | 2000-02-24 | 2001-09-03 | Xenon Genetics Inc | Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents |
| ATE402262T1 (de) | 2000-09-26 | 2008-08-15 | Xenon Pharmaceuticals Inc | Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden |
| MX2007003318A (es) * | 2004-09-20 | 2007-05-18 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
| US7767677B2 (en) * | 2004-09-20 | 2010-08-03 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| WO2007046867A2 (en) * | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their uses as therapeutic agents |
| MY153263A (en) * | 2006-08-15 | 2015-01-29 | Novartis Ag | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels |
| RU2009110254A (ru) * | 2006-08-24 | 2010-09-27 | Новартис АГ (CH) | Производные 2-(пиразин-2-ил)тиазола и 2-(1н-пиразол-3-ил)тиразола и связанные с ним соединения в качестве ингибиторов стеароил-соа десатуразы для лечения метаболических, сердечно-сосудистых и других нарушений |
| KR20090053923A (ko) * | 2006-09-22 | 2009-05-28 | 노파르티스 아게 | 헤테로시클릭 유기 화합물 |
| US8068738B2 (en) * | 2007-02-21 | 2011-11-29 | Tte Technology, Inc. | System and method for decoding infra-red (IR) signals |
| NZ587350A (en) * | 2008-02-20 | 2012-07-27 | Novartis Ag | Thiazole derivatives featuring an imidazolidine or triazole derivative as inhibitors of stearoyl-CoA desaturase |
-
2010
- 2010-10-01 PE PE2012000427A patent/PE20121439A1/es not_active Application Discontinuation
- 2010-10-01 MX MX2012003938A patent/MX2012003938A/es not_active Application Discontinuation
- 2010-10-01 WO PCT/EP2010/064672 patent/WO2011039358A1/en active Application Filing
- 2010-10-01 IN IN1913DEN2012 patent/IN2012DN01913A/en unknown
- 2010-10-01 JP JP2012531447A patent/JP2013506638A/ja active Pending
- 2010-10-01 SG SG2012013066A patent/SG178869A1/en unknown
- 2010-10-01 KR KR1020127011127A patent/KR20120080226A/ko not_active Application Discontinuation
- 2010-10-01 CA CA2776294A patent/CA2776294A1/en not_active Abandoned
- 2010-10-01 US US13/391,900 patent/US20130011361A1/en not_active Abandoned
- 2010-10-01 CN CN201080044452XA patent/CN102574841A/zh active Pending
- 2010-10-01 EA EA201200545A patent/EA201200545A1/ru unknown
- 2010-10-01 EP EP10761003A patent/EP2483264A1/en not_active Withdrawn
- 2010-10-01 AU AU2010302577A patent/AU2010302577A1/en not_active Abandoned
- 2010-10-01 BR BR112012007509A patent/BR112012007509A2/pt not_active IP Right Cessation
-
2012
- 2012-02-21 TN TNP2012000085A patent/TN2012000085A1/en unknown
- 2012-02-23 IL IL218294A patent/IL218294A0/en unknown
- 2012-02-24 ZA ZA2012/01390A patent/ZA201201390B/en unknown
- 2012-03-20 CR CR20120134A patent/CR20120134A/es unknown
- 2012-03-30 CL CL2012000797A patent/CL2012000797A1/es unknown
- 2012-04-03 CO CO12056222A patent/CO6761294A2/es not_active Application Discontinuation
- 2012-04-26 MA MA34807A patent/MA33693B1/fr unknown
- 2012-04-27 EC ECSP12011837 patent/ECSP12011837A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20120134A (es) | 2012-05-17 |
| PE20121439A1 (es) | 2012-11-06 |
| MX2012003938A (es) | 2012-08-03 |
| AU2010302577A1 (en) | 2012-03-15 |
| TN2012000085A1 (en) | 2013-09-19 |
| CN102574841A (zh) | 2012-07-11 |
| IL218294A0 (en) | 2012-04-30 |
| WO2011039358A1 (en) | 2011-04-07 |
| BR112012007509A2 (pt) | 2016-11-22 |
| MA33693B1 (fr) | 2012-10-01 |
| EA201200545A1 (ru) | 2012-12-28 |
| JP2013506638A (ja) | 2013-02-28 |
| CA2776294A1 (en) | 2011-04-07 |
| KR20120080226A (ko) | 2012-07-16 |
| CO6761294A2 (es) | 2013-09-30 |
| IN2012DN01913A (es) | 2015-07-24 |
| EP2483264A1 (en) | 2012-08-08 |
| ECSP12011837A (es) | 2012-06-29 |
| ZA201201390B (en) | 2012-10-31 |
| SG178869A1 (en) | 2012-04-27 |
| US20130011361A1 (en) | 2013-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014002556A1 (es) | Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras. | |
| AR092925A1 (es) | Derivados de exendina-4 como agonistas duales de glp1 / glucagon | |
| CY1119582T1 (el) | Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη | |
| CY1121153T1 (el) | Παραγωγα εξενδινης-4 ως διπλοι glp1/gιp- ή τριγωνικοι αγωνιστες glp1/gιp/γλυκαγονης | |
| CL2009000173A1 (es) | Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros. | |
| UY32094A (es) | Derivados heterocíclicos, procesos para su preparación, medicamentos que comprenden dichos compuestos y su uso. | |
| CL2013002414A1 (es) | Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension. | |
| CL2013001104A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras. | |
| CL2013000716A1 (es) | Un profarmaco o una sal del mismo que comprende un conjugado de exendina-conector; procedimiento de preparacion de dicho profarmaco; compuestos intermediarios; composicion farmaceutica que lo comprende, util para mejorar el control glucemico en pacientes con diabetes de tipo 2. | |
| AR098738A1 (es) | Análogos del péptido exendina-4 no acilados | |
| CL2012000797A1 (es) | Compuestos derivados de pirazol, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que los comprende; y su uso para el tratamiento de una enfermedad o condicion tal como sindrome metabolico, diabetes, resistencia a la insulina, complicaciones diabeticas y trastornos del peso corporal. | |
| CL2008001125A1 (es) | Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad. | |
| CL2008001126A1 (es) | Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad. | |
| CL2013002053A1 (es) | Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct | |
| CL2014003421A1 (es) | Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad. | |
| CL2008000198A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis. | |
| CL2008001821A1 (es) | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. | |
| CL2007003440A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida | |
| CL2008001612A1 (es) | 5-(3-hidroxi-7-sustituido-naftalen-2-il)-1, 1-dioxo-[1,2,5]tiadiazolidin-3-ona; su uso para tratar un trastorno hiperproliferativo; la composicion farmaceutica que los contiene; y sus procesos de preparacion. | |
| GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
| ES2445846R1 (es) | Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos | |
| MX2013013242A (es) | Combinacion farmaceutica para mejorar el control glucemico como terapia adicional a la insulina basal. | |
| UY36779A (es) | Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón | |
| CL2009000889A1 (es) | Compuestos derivados de 2-oxo-2,5-dihidro pirrol propionamida, activadores de glucoquinasa; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compestos; y su uso en el tratamiento de diabetes mellitus. | |
| CL2007001022A1 (es) | Compuestos derivados de 1h-indol-2-carboxamida; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento y/o prevencion de enfermedades asociadas con la modulacion de los receptores de h3 tal como obesidad, diabetes tipo ii y |